RICHMOND, British Columbia, June 4, 2007 (PRIME NEWSWIRE) -- BioCurex Inc. (OTCBB:BOCX) today announced that it is making progress on its initiative to develop point-of-care tests (also called 'Rapid Tests').
The company is pleased to report that preliminary results show it is possible to make such RECAF-based rapid tests for cancer detection.
The device used in the research is similar to the pregnancy tests that are commonly available for home use. Further details, as well as pictures of results are available at: http://biocurex.com/CUREXHTML/news/rapidtests.html
Given the small number of samples tested, it is impossible to tell, at this time, whether or not it might be necessary to use a small portable instrument similar to the ones used to monitor blood sugar to read the intensity of the color of the band.
These experiments are very preliminary, and therefore no statistical conclusions can be drawn from this small number of samples. Furthermore, a significant amount of work needs to be done to perfect the test. Yet, the initial results strongly suggest that such a rapid test for cancer in general is feasible. This RECAF test format is intended to be used by physicians as a first approximation to the diagnosis of cancer and it will require confirmation by the more accurate, quantitative RECAF test performed by a clinical laboratory.
The company estimates the potential market for this test to be substantial.
"We are very pleased with the preliminary results of our intensive R & D efforts and view this potential product as an important addition to our growing line of cancer detection technologies," stated Ricardo Moro, President and CEO. "The successful development of a rapid test for detecting cancer will position BioCurex as an industry innovator in this billion dollar market."
About BioCurex:
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells.
BioCurex has signed a licensing agreement with Abbott Laboratories for BioCurex's RECAF(tm) Cancer technology as outlined in a joint press release dated March 29, 2005. The release noted that the cancer marker RECAF(tm) has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others.
To read more about the Company, please visit the News section in our web site (www.biocurex.com).
Note:
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.